secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0001764013-23-000097
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant shareholders elect three directors, ratify EY, approve exec compensation
--------------------------------------------------------------------------------

- Peter Salzmann (98.5M for, 17.7M withheld), Douglas Hughes (96.6M for, 19.6M withheld), George Migausky (96.6M for, 19.7M withheld) elected to board.
- Ratification of Ernst & Young as independent auditor for FY2024: 121,206,460 for, 5,261 against, 1,355 abstain.
- Non-binding advisory approval of named executive officer compensation: 115,397,185 for, 825,452 against, 8,173 abstain, 4,982,266 broker non-votes.
- Annual meeting turnout ~93% of outstanding shares (121,213,076 shares represented).
- All three proposals passed; no material changes to governance disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000097/0001764013-23-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000097/imvt-20230821.htm
  HTML page:      https://secwatch.observer/filing/0001764013-23-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer